Innate Pharma has been granted a patent for a composition involving therapeutic antibodies conjugated to ß-1,6-glucan oligomers. The invention includes methods of making and using these conjugates for therapeutic purposes. GlobalData’s report on Innate Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innate Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Innate Pharma's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Therapeutic antibody conjugated to ß-1,6-glucan oligomers
A recently granted patent (Publication Number: US11865135B2) discloses a composition comprising conjugates according to Formula II. The composition includes a Therapeutic Antibody with specific complementarity determining region (CDR) amino acid sequences, such as SEQ ID NO: 30, 31, 32, 33, 34, and 35. The patent specifies the use of Therapeutic Antibodies like trastuzumab and cetuximab in the composition, targeting tumor growth in cancers associated with overexpression and/or amplification of specific target moieties.
Moreover, the patent details a method for inhibiting tumor growth in subjects with cancers overexpressing target moieties like EGFR or HER2/neu by administering the disclosed composition. The target moieties include a range of proteins like CEACAM5, CD20, CD33, EGFR, HER2/neu, VEGF-A, and more. The Therapeutic Antibodies mentioned in the patent, including cetuximab, trastuzumab, and others, are crucial components of the composition for effective tumor growth inhibition in various types of cancers, such as colorectal cancer, breast cancer, lung cancer, and head and neck cancer. The patent provides a comprehensive guide for utilizing the disclosed composition and method for targeted cancer therapy.
To know more about GlobalData’s detailed insights on Innate Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
